Design of Future Rabies Biologics and Antiviral Drugs

Advances in Virus Research

Volumn 79, Issue , 2011, Pages 345-363

  Smith, Todd G ^a   Wu, Xianfu ^a   Franka, Richard ^a   E Rupprecht, Charles ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antiviral drugs; Monoclonal antibodies; Postexposure prophylaxis; Rabies Vaccine; Rabies virus

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL PRODUCT; RABIES VACCINE; VIRUS ANTIBODY;

ANIMAL; BOOK; DRUG EFFECT; HUMAN; IMMUNOLOGY; METHODOLOGY; POST EXPOSURE PROPHYLAXIS; RABIES; RABIES VIRUS; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BIOLOGICAL PRODUCTS; HUMANS; POST-EXPOSURE PROPHYLAXIS; RABIES; RABIES VACCINES; RABIES VIRUS;

EID: 79956124692     PISSN: 00653527     EISSN: 15578399     Source Type: Book Series    
DOI: 10.1016/B978-0-12-387040-7.00016-0     Document Type: Book

References (116)

1. Abelseth M.K. An attenuated rabies vaccine for domestic animals produced in tissue culture. Can. Vet. J. 1964, 5:279-286.
2. Ashraf S., Singh P.K., Yadav D.K., Shahnawaz M., Mishra S., Sawant S.V., Tuli R. High level expression of surface glycoprotein of rabies virus in tobacco leaves and its immunoprotective activity in mice. J. Biotechnol. 2005, 119:1-14.
3. Ashwathnarayana D.H., Madhusudana S.N., Sampath G., Sathpathy D.M., Mankeshwar R., Ravish H.H., Ullas P.T., Behra T.R., Sudarshan M.K., Gangaboraiah, Shamanna M. A comparative study on the safety and immunogenicity of purified duck embryo cell vaccine (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purified vero cell rabies vaccine (PVRV, Verorab). Vaccine 2009, 28:148-151.
4. Atanasiu P., Perrin P., Segre L., Manganas O. Evaluation and comparative studies of inactivated rabies vaccines obtained in the heterologous diploid and polyploid cells (HAK, BHK and VERO). Dev. Biol. Stand. 1981, 50:173-182.
5. Ayele W., Fekadu M., Zewdie B., Beyene M., Bogale Y., Mocha K., Egziabher F.G. Immunogenicity and efficacy of Fermi-type nerve tissue rabies vaccine in mice and in humans undergoing post-exposure prophylaxis for rabies in Ethiopia. Ethiop. Med. J. 2001, 39:313-321.
6. Baer G.M., Moore S.A., Shaddock J.H., Levy H.B. An effective rabies treatment in exposed monkeys: A single dose of interferon inducer and vaccine. Bull. World Health Organ. 1979, 57:807-813.
7. Bakker A.B., Marissen W.E., Kramer R.A., Rice A.B., Weldon W.C., Niezgoda M., Hanlon C.A., Thijsse S., Backus H.H., de Kruif J., Dietzschold B., Rupprecht C.E., et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J. Virol. 2005, 79:9062-9068.
8. Bakker A.B., Python C., Kissling C.J., Pandya P., Marissen W.E., Brink M.F., Lagerwerf F., Worst S., van Corven E., Kostense S., Hartmann K., Weverling G.J., et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: Safety, tolerability, and neutralizing activity. Vaccine 2008, 26:5922-5927.
9. Barth R., Bijok U., Grushkau H., Smerdel J., Vodopija J. Purified chicken embryo cell rabies vaccine for human use. Lancet 1983, 1:700.
10. Benmansour A., Leblois H., Coulon P., Tuffereau C., Gaudin Y., Flamand A., Lafay F. Antigenicity of rabies virus glycoprotein. J. Virol. 1991, 65:4198-4203.
11. Blanpied T.A., Clarke R.J., Johnson J.W. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J. Neurosci. 2005, 25:3312-3322.
12. Brandao P.E., Castilho J.G., Fahl W., Carnieli P., Oliveira Rde N., Macedo C.I., Carrieri M.L., Kotait I. Short-interfering RNAs as antivirals against rabies. Braz. J. Infect. Dis. 2007, 11:224-225.
13. Bresink I., Danysz W., Parsons C.G., Mutschler E. Different binding affinities of NMDA receptor channel blockers in various brain regions-Indication of NMDA receptor heterogeneity. Neuropharmacology 1995, 34:533-540.
14. Brzozka K., Finke S., Conzelmann K.K. Identification of the rabies virus alpha/beta interferon antagonist: Phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3. J. Virol. 2005, 79:7673-7681.
15. Brzozka K., Finke S., Conzelmann K.K. Inhibition of interferon signaling by rabies virus phosphoprotein P: Activation-dependent binding of STAT1 and STAT2. J. Virol. 2006, 80:2675-2683.
16. Bussereau F., Ermine A. Effects of heteropolyanions and nucleoside analogues on rabies virus: In vitro study of syntheses and viral production. Ann. Inst. Pasteur Virol. 1983, 134:487-506.
17. Bussereau F., Chermann J.C., De Clercq D., Hannoun C. Search for compounds which have an inhibitory effect on rhabdovirus multiplication in vitro. Ann. Inst. Pasteur Virol. 1983, 134:127-134.
18. Bussereau F., Picard M., Blancou J., Sureau P. Treatment of rabies in mice and foxes with antiviral compounds. Acta Virol. 1988, 32:33-49.
19. Castel G., Chteoui M., Caignard G., Prehaud C., Mehouas S., Real E., Jallet C., Jacob Y., Ruigrok R.W., Tordo N. Peptides that mimic the amino-terminal end of the rabies virus phosphoprotein have antiviral activity. J. Virol. 2009, 83:10808-10820.
20. Champion J.M., Kean R.B., Rupprecht C.E., Notkins A.L., Koprowski H., Dietzschold B., Hooper D.C. The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J. Immunol. Methods 2000, 235:81-90.
21. Culbertson C.G., Peck F.B., Powell H.M. Duck-embryo rabies vaccine: Study of fixed virus vaccine grown in embryonated duck eggs and killed with beta-propiolactone (BPL). J. Am. Med. Assoc. 1956, 162:1373-1376.
22. Cupo P., de Azevedo-Marques M.M., Sarti W., Hering S.E. Proposal of abolition of the skin sensitivity test before equine rabies immune globulin application. Rev. Inst. Med. Trop. São Paulo 2001, 43:51-53.
23. De Clercq E. Antivirals and antiviral strategies. Nat. Rev. Microbiol. 2004, 2:704-720.
24. De Kruif J., Bakker A.B., Marissen W.E., Kramer R.A., Throsby M., Rupprecht C.E., Goudsmit J. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu. Rev. Med. 2007, 58:359-368.
25. Depoux R. Fixed rabies virus and interferon (virus rabique fixe et interféron). C. R. Hebd. Seances Acad. Sci. 1965, 260:354-356.
26. Dhankhar P., Vaidya S.A., Fishbien D.B., Meltzer M.I. Cost effectiveness of rabies post exposure prophylaxis in the United States. Vaccine 2008, 26:4251-4255.
27. Dietzschold B., Gore M., Casali P., Ueki Y., Rupprecht C.E., Notkins A.L., Koprowski H. Biological characterization of human monoclonal antibodies to rabies virus. J. Virol. 1990, 64:3087-3090.
28. Ertl H.C. Rabies DNA vaccines for protection and therapeutic treatment. Expert Opin. Biol. Ther. 2003, 3:639-644.
29. Faber M., Pulmanausahakul R., Hodawadekar S.S., Spitsin S., McGettigan J.P., Schnell M.J., Dietzschold B. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J. Virol. 2002, 76:3374-3381.
30. Famm K., Hansen L., Christ D., Winter G. Thermodynamically stable aggregation-resistant antibody domains through directed evolution. J. Mol. Biol. 2008, 376:926-931.
31. Fermi C. On immunization against rabies (über die immunisierung gegen wutkrankheit). Med. Microbiol. Immunol. 1908, 58:233-276.
32. Fournier P., Montagnon B., Vincent-Falquet J.C., Ajjan N., Drucker J., Roumiantzeff M. A new vaccine produced from rabies virus cultivated on Vero cells. Improvements in Rabies Post-exposure Treatment 1985, 129-136. Zagreb Institute of Public Health, Zagreb. I. Vodopija, K.G. Nicholson, S. Smerdel, U. Bijok (Eds.).
33. Fuenzalida E., Palacios R., Borgono J.M. Antirabies antibody response in man to vaccine made from infected suckling-mouse brains. Bull. World Health Organ. 1964, 30:431-436.
34. Gluck R., Wegmann A., Germanier R., Keller H., Hess M.W., Kraus-Ruppert R., Wandeler A.I. A new, highly immunogenic duck embryo rabies vaccine. Lancet 1984, 1:844-845.
35. Gluck R., Matthieu J.M., Wegmann A., Mean F. Absence of myelin basic protein in an improved purified duck embryo rabies vaccine. Neurochem. Pathol. 1986, 4:69-75.
36. Goudsmit J., Marissen W.E., Weldon W.C., Niezgoda M., Hanlon C.A., Rice A.B., Kruif J., Dietzschold B., Bakker A.B., Rupprecht C.E. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J. Infect. Dis. 2006, 193:796-801.
37. Grosenbaugh D.A., Maki J.L., Rupprecht C.E., Wall D.K. Rabies challenge of captive striped skunks (Mephitis mephitis) following oral administration of a live vaccinia-vectored rabies vaccine. J. Wildl. Dis. 2007, 43:124-128.
38. Hendrick M.J., Shofer F.S., Goldschmidt M.H., Haviland J.C., Schelling S.H., Engler S.J., Gliatto J.M. Comparison of fibrosarcomas that developed at vaccination sites and at nonvaccination sites in cats: 239 cases (1991-1992). J. Am. Vet. Med. Assoc. 1994, 205:1425-1429.
39. Houimel M., Dellagi K. Isolation and characterization of human neutralizing antibodies to rabies virus derived from a recombinant immune antibody library. J. Virol. Methods 2009, 161:205-215.
40. Hu W.T., Willoughby R.E., Dhonau H., Mack K.J. Long-term follow-up after treatment of rabies by induction of coma. N. Engl. J. Med. 2007, 357:945-946.
41. Ito N., Sugiyama M., Yamada K., Shimizu K., Takayama-Ito M., Hosokawa J., Minamoto N. Characterization of M gene-deficient rabies virus with advantages of effective immunization and safety as a vaccine strain. Microbiol. Immunol. 2005, 49:971-979.
42. Jackson A.C., Warrell M.J., Rupprecht C.E., Ertl H.C., Dietzschold B., O'Reilly M., Leach R.P., Fu Z.F., Wunner W.H., Bleck T.P., Wilde H. Management of rabies in humans. Clin. Infect. Dis. 2003, 36:60-63.
43. Jahrling P.B., Hesse R.A., Eddy G.A., Johnson K.M., Callis R.T., Stephen E.L. Lassa virus infection of rhesus monkeys: Pathogenesis and treatment with ribavirin. J. Infect. Dis. 1980, 141:580-589.
44. Kammer A.R., Ertl H.C. Rabies vaccines: From the past to the 21st century. Hybrid. Hybridomics 2002, 21:123-127.
45. Kass P.H., Barnes W.G., Spangler W.L., Chomel B.B., Culbertson M.R. Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats. J. Am. Vet. Med. Assoc. 1993, 203:396-405.
46. Ko K.S., Tekoah Y., Rudd P.M., Harvey D.J., Dwek R.A., Spitsin S., Hanlon C.A., Rupprecht C., Dietzschold B., Golovkin M., Koprowski H. Function and glycosylation of plant-derived antiviral monoclonal antibody. Proc. Natl. Acad. Sci. USA 2003, 100:8013-8018.
47. Kondo A. Growth characteristics of rabies virus in primary chick embryo cells. Virology 1965, 27:199-204.
48. Koprowski H., Cox H.R. Studies on chick embryo adapted rabies virus: Culture characteristics and pathogenicity. J. Immunol. 1948, 60:533-554.
49. Kramer R.A., Marissen W.E., Goudsmit J., Visser T.J., Clijsters-Van der Horst M., Bakker A.Q., de Jong M., Jongeneelen M., Thijsse S., Backus H.H., Rice A.B., Weldon W.C., et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur. J. Immunol. 2005, 35:2131-2145.
50. Kreindel S.M., McGuill M., Meltzer M., Rupprecht C., DeMaria A. The cost of rabies postexposure prophylaxis: One state's experience. Public Health Rep. 1998, 113:247-251.
51. Kureishi A., Xu L.Z., Wu H., Stiver H.G. Rabies in China: Recommendations for control. Bull. World Health Organ. 1992, 70:443-450.
52. Lafay F., Benejean J., Tuffereau C., Flamand A., Coulon P. Vaccination against rabies: Construction and characterization of SAG2, a double avirulent derivative of SADBern. Vaccine 1994, 12:317-320.
53. Lafon M. Modulation of the immune response in the nervous system by rabies virus. Curr. Top. Microbiol. Immunol. 2005, 289:239-258.
54. Lafon M., Wiktor T.J., Macfarlan R.I. Antigenic sites on the CVS rabies virus glycoprotein: Analysis with monoclonal antibodies. J. Gen. Virol. 1983, 64:843-851.
55. Lang J., Attanath P., Quiambao B., Singhasivanon V., Chanthavanich P., Montalban C., Lutsch C., Pepin-Covatta S., Le Mener V., Miranda M., Sabchareon A. Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine. Acta Trop. 1998, 70:317-333.
56. Lang J., Gravenstein S., Briggs D., Miller B., Froeschle J., Dukes C., Le Mener V., Lutsch C. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies. Biologicals 1998, 26:7-15.
57. Lau J.Y., Tam R.C., Liang T.J., Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002, 35:1002-1009.
58. Leach C.N., Johnson H.N. Human rabies, with special reference to virus distribution and titer. Am. J. Trop. Med. 1940, s1-20:335-340.
59. Lee C.M., Iorno N., Sierro F., Christ D. Selection of human antibody fragments by phage display. Nat. Protoc. 2007, 2:3001-3008.
60. Lin F.T. The protective effect of the large-scale use of PHKC rabies vaccine in humans in China. Bull. World Health Organ. 1990, 68:449-454.
61. Lin F., Zeng F., Lu L., Lu X., Zen R., Yu Y., Chen N. The primary hamster kidney cell rabies vaccine: Adaptation of viral strain, production of vaccine, and pre- and postexposure treatment. J. Infect. Dis. 1983, 147:467-473.
62. Lingappa V.R., Lingappa J.R. Recent insights into biological regulation from cell-free protein-synthesizing systems. Mt. Sinai J. Med. 2005, 72:141-160.
63. Lockhart B.P., Tsiang H., Cecaldi P.E., Guillemer S. Ketamine-mediated inhibition of rabies virus infection in vitro and in rat brain. Antiviral Chem. Chemother. 1991, 2:9-15.
64. Lockhart B.P., Tordo N., Tsiang H. Inhibition of rabies virus transcription in rat cortical neurons with the dissociative anesthetic ketamine. Antimicrob. Agents Chemother. 1992, 36:1750-1755.
65. Loza-Rubio E., Rojas E., Gomez L., Olivera M.T., Gomez-Lim M.A. Development of an edible rabies vaccine in maize using the Vnukovo strain. Dev. Biol. (Basel) 2008, 131:477-482.
66. Marissen W.E., Kramer R.A., Rice A., Weldon W.C., Niezgoda M., Faber M., Slootstra J.W., Meloen R.H., Clijsters-van der Horst M., Visser T.J., Jongeneelen M., Thijsse S., et al. Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: Fine mapping and escape mutant analysis. J. Virol. 2005, 79:4672-4678.
67. McGarvey P.B., Hammond J., Dienelt M.M., Hooper D.C., Fu Z.F., Dietzschold B., Koprowski H., Michaels F.H. Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnology 1995, 13:1484-1487.
68. Merigan T.C., Baer G.M., Winkler W.G., Bernard K.W., Gibert C.G., Chany C., Veronesi R. Human leukocyte interferon administration to patients with symptomatic and suspected rabies. Ann. Neurol. 1984, 16:82-87.
69. Modelska A., Dietzschold B., Sleysh N., Fu Z.F., Steplewski K., Hooper D.C., Koprowski H., Yusibov V. Immunization against rabies with plant-derived antigen. Proc. Natl. Acad. Sci. USA 1998, 95:2481-2485.
70. Muller T., Dietzschold B., Ertl H., Fooks A.R., Freuling C., Fehlner-Gardiner C., Kliemt J., Meslin F.X., Franka R., Rupprecht C.E., Tordo N., Wanderler A.I., et al. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl. Trop. Dis. 2009, 3:e542.
71. Nadin-Davis S.A., Fehlner-Gardiner C. Lyssaviruses: Current trends. Adv. Virus Res. 2008, 71:207-250.
72. Nagarajan T., Rupprecht C.E., Dessain S.K., Rangarajan P.N., Thiagarajan D., Srinivasan V.A. Human monoclonal antibody and vaccine approaches to prevent human rabies. Curr. Top. Microbiol. Immunol. 2008, 317:67-101.
73. Compendium of animal rabies prevention and control. J. Am. Vet. Med. Assoc. 2008, 232:1478-1486. National Association of State Public Health Veterinarians Committee.
74. Osinubi M.O., Wu X., Franka R., Niezgoda M., Nok A.J., Ogunkoya A.B., Rupprecht C.E. Enhancing comparative rabies DNA vaccine effectiveness through glycoprotein gene modifications. Vaccine 2009, 27:7214-7218.
75. Plotkin S.A. Rabies. Clin. Infect. Dis. 2000, 30:4-12.
76. Porter R.H., Greenamyre J.T. Regional variations in the pharmacology of NMDA receptor channel blockers: Implications for therapeutic potential. J. Neurochem. 1995, 64:614-623.
77. Powers C.N., Peavy D.L., Knight V. Selective inhibition of functional lymphocyte subpopulations by ribavirin. Antimicrob. Agents Chemother. 1982, 22:108-114.
78. Prosniak M., Faber M., Hanlon C.A., Rupprecht C.E., Hooper D.C., Dietzschold B. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J. Infect. Dis. 2003, 188:53-56.
79. Real E., Rain J.C., Battaglia V., Jallet C., Perrin P., Tordo N., Chrisment P., D'Alayer J., Legrain P., Jacob Y. Antiviral drug discovery strategy using combinatorial libraries of structurally constrained peptides. J. Virol. 2004, 78:7410-7417.
80. Rojas-Anaya E., Loza-Rubio E., Olivera-Flores M.T., Gomez-Lim M. Expression of rabies virus G protein in carrots (Daucus carota). Transgenic Res. 2009, 18:911-919.
81. Roumiantzeff M., Ajjan N., Branche R., Fournier P., Montagnon B., Trotemann P., Vincent-Falquet J.C. Rabies vaccine produced in cell-culture: Production and control and clinical results. Applied Virology 1984, 241-296. Academic Press, Orlando, FL. E. Kurstak (Ed.).
82. Rubin D.H., Ruley H.E. Cellular genetics of host susceptibility and resistance to virus infection. Crit. Rev. Eukaryot. Gene Expr. 2006, 16:155-170.
83. Ruegsegger J.M., Black J., Sharpless G.R. Primary antirabies immunization of man with HEP flury virus vaccine. Am. J. Public Health 1961, 51:706-716.
84. Satpathy D.M., Sahu T., Behera T.R. Equine rabies immunoglobulin: A study on its clinical safety. J. Indian Med. Assoc. 2005, 103(238):241-242.
85. Semple D. The preparation of a safe and efficient antirabic vaccine, Vol. 44 1911, Sci. Mem. Med. Sanit. Dept., India.
86. Sharpless G.R., Black J., Cox H.R., Ruegsegger J.M. Preliminary observations in primary antirabies immunization of man with different types of high-egg-passage Flury virus. Bull. World Health Organ. 1957, 17:905-910.
87. Shoji Y., Inoue S., Nakamichi K., Kurane I., Sakai T., Morimoto K. Generation and characterization of P gene-deficient rabies virus. Virology 2004, 318:295-305.
88. Sloan S.E., Hanlon C., Weldon W., Niezgoda M., Blanton J., Self J., Rowley K.J., Mandell R.B., Babcock G.J., Thomas W.D., Rupprecht C.E., Ambrosino D.M. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 2007, 25:2800-2810.
89. Steck F., Wandeler A., Bichsel P., Capt S., Hafliger U., Schneider L. Oral immunization of foxes against rabies. Laboratory and field studies. Comp. Immunol. Microbiol. Infect. Dis. 1982, 5:165-171.
90. Stoof J.C., Booij J., Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: New possibilities for therapeutic applications?. Clin. Neurol. Neurosurg. 1992, 94(Suppl.):S4-S6.
91. Suntharasamai P., Chanthavanich P., Warrell M.J., Looareesuwan S., Karbwang J., Supanaranond W., Phillips R.E., Jansawan W., Xueref C., Pouradier-Duteil X., Warrell D.A. Purified Vero cell rabies vaccine and human diploid cell strain vaccine: Comparison of neutralizing antibody responses to post-exposure regimens. J. Hyg. 1986, 96:483-489.
92. Superti F., Seganti L., Pana A., Orsi N. Effect of amantadine on rhabdovirus infection. Drugs Exp. Clin. Res. 1985, 11:69-74.
93. Tam R.C., Ramasamy K., Bard J., Pai B., Lim C., Averett D.R. The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels. Antimicrob. Agents Chemother. 2000, 44:1276-1283.
94. Tordo N. New strategies for diagnosis and therapy of Lyssaviruses 2010.
95. Ueki Y., Goldfarb I.S., Harindranath N., Gore M., Koprowski H., Notkins A.L., Casali P. Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J. Exp. Med. 1990, 171:19-34.
96. Vodopija I., Clarke H.F. Human vaccination against rabies. The Natural History of Rabies 1991, 571-595. CRC Press, Boca Raton, FL. G.M. Baer (Ed.).
97. Vos A., Neubert A., Pommerening E., Muller T., Dohner L., Neubert L., Hughes K. Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration. J. Gen. Virol. 2001, 82:2191-2197.
98. Wang Y., Rowley K.J., Booth B.J., Sloan S.E., Fehlner-Gardiner C., Wandeler A., Ambrosino D.M., Babcock G.J. G glycoprotein amino acid residues required for RAB1 neutralization are conserved in rabies virus street isolates 2009.
99. Warrell M.J., White N.J., Looareesuwan S., Phillips R.E., Suntharasamai P., Chanthavanich P., Riganti M., Fisher-Hoch S.P., Nicholson K.G., Manatsathit S., Vannaphan S., Warrell D.A. Failure of interferon alfa and tribavirin in rabies encephalitis. Br. Med. J. 1989, 299:830-833.
100. Weinmann E., Majer M., Hilfenhaus J. Intramuscular and/or intralumbar postexposure treatment of rabies virus-infected cynomolgus monkeys with human interferon. Infect. Immun. 1979, 24:24-31.
101. Weli S.C., Scott C.A., Ward C.A., Jackson A.C. Rabies virus infection of primary neuronal cultures and adult mice: Failure to demonstrate evidence of excitotoxicity. J. Virol. 2006, 80:10270-10273.
102. Wiktor T.J., Clark H.F. Chronic rabies virus infection of cell-cultures. Infect. Immun. 1972, 6:988-995.
103. Wiktor T.J., Fernandes M.V., Koprowski H. Cultivation of rabies virus in human diploid cell strain Wi-38. J. Immunol. 1964, 93:353-366.
104. Wiktor T.J., Macfarlan R.I., Reagan K.J., Dietzschold B., Curtis P.J., Wunner W.H., Kieny M.P., Lathe R., Lecocq J.P., Mackett M., et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc. Natl. Acad. Sci. USA 1984, 81:7194-7198.
105. Wilde H. Failures of post-exposure rabies prophylaxis. Vaccine 2007, 25:7605-7609.
106. Wilde H., Chutivongse S. Equine rabies immune globulin: A product with an undeserved poor reputation. Am. J. Trop. Med. Hyg. 1990, 42:175-178.
107. Wilde H., Chomchey P., Prakongsri S., Puyaratabandhu P., Chutivongse S. Adverse effects of equine rabies immune globulin. Vaccine 1989, 7:10-11.
108. Willoughby R.E., Tieves K.S., Hoffman G.M., Ghanayem N.S., Amlie-Lefond C.M., Schwabe M.J., Chusid M.J., Rupprecht C.E. Survival after treatment of rabies with induction of coma. N. Engl. J. Med. 2005, 352:2508-2514.
109. Wu X., Rupprecht C.E. Glycoprotein gene relocation in rabies virus. Virus Res. 2008, 131:95-99.
110. Wu X., Franka R., Svoboda P., Pohl J., Rupprecht C.E. Development of combined vaccines for rabies and immunocontraception. Vaccine 2009, 27:7202-7209.
111. Wu X., Franka R., Jackson F.R., Carson W.C., Ellison J.A., Rupprecht C.E. Two copies of GnRH fused to rabies virus glycoprotein induce efficient immunocontraception in a mouse model 2010.
112. Wunner W.H., Briggs D.J. Rabies in the 21 century. PLoS Negl. Trop. Dis. 2010, 4:591.
113. Wunner W.H., Pallatroni C., Curtis P.J. Selection of genetic inhibitors of rabies virus. Arch. Virol. 2004, 149:1653-1662.
114. Xiang Z., Gao G., Reyes-Sandoval A., Cohen C.J., Li Y., Bergelson J.M., Wilson J.M., Ertl H.C. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 2002, 76:2667-2675.
115. Yarosh O.K., Wandeler A.I., Graham F.L., Campbell J.B., Prevec L. Human adenovirus type 5 vectors expressing rabies glycoprotein. Vaccine 1996, 14:1257-1264.
116. Yoshino K., Taniguchi S., Arai K. Plaque assay of rabies virus in chick embryo cells. Arch. Virol. 1966, 18:370-373.